Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$93.06

0.18 (0.19%)

, PFE

Pfizer

$35.86

0.35 (0.99%)

08:32
05/15/18
05/15
08:32
05/15/18
08:32

Sarepta price target raised to $121 from $88 at Leerink

Leerink analyst Joseph Schwartz raised his price target for Sarepta (SRPT) to $121 from $88, while reiterating an Outperform rating on the shares. The analyst notes that Sarepta is one of three companies developing microdystrophin gene therapy for Duchenne muscular dystrophy, in competition with Pfizer (PFE) who acquired Bamboo, and Solid Biosciences (SLDB). With Solid's clinical hold still in place, Sarepta could potentially be first-to-market, and is expected to report the first clinical data for a micro-dystrophin candidate at their R&D day on June 19, he adds.

SRPT

Sarepta

$93.06

0.18 (0.19%)

PFE

Pfizer

$35.86

0.35 (0.99%)

SLDB

Solid Biosciences

$21.71

-0.79 (-3.51%)

  • 16

    May

  • 20

    May

  • 05

    Jun

SRPT Sarepta
$93.06

0.18 (0.19%)

05/11/18
LEHM
05/11/18
UPGRADE
Target $107
LEHM
Overweight
Sarepta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Gena Wang upgraded Sarepta Therapeutics to Overweight and raised her price target for the shares to $107 from $55. The "good safety profile" of the company's PMO franchise could replace its "suboptimal" PMO franchise, Wang tells investors in a research note. The analyst, while seeing a limited opportunity in Europe for Exondys 51, believes Sarepta's microdystrophin program has a "reasonable chance" to show promising clinical activity.
05/10/18
NOMU
05/10/18
NO CHANGE
Target $131
NOMU
Buy
Nomura recommends owning Sarepta for 'second dose' of upside
An overlooked takeaway from Sarepta Therapeutics' earnings call is the company highlighting its "aggressive and ambitious" plans to progress its gene therapy program, Nomura Instinet analyst Christopher Marai tells investors in a research note. He recommends recommend owning the stock for a "second dose of potential upside." The analyst has a Buy rating on Sarepta with a $131 price target.
05/07/18
NEED
05/07/18
NO CHANGE
Target $109
NEED
Buy
Sarepta price target raised to $109 from $75 at Needham
Needham analyst Chad Messer raised his price target on Sarepta to $109 and kept his Buy rating after the company's in-line Q1 results. Messer cites Sarepta's announcing an R&D presentation on June 19th to discuss its "growing pipeline", adding that the company had already promised "at least 2 patients worth of safety and gene expression data from the ongoing microdystrophin gene therapy program". The analyst expects Sarepta stock to reflect investor optimism typically given to early data from gene therapy companies.
05/07/18
HCWC
05/07/18
NO CHANGE
Target $96
HCWC
Buy
Sarepta price target raised to $96 from $90 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Sarepta Therapeutics to $96 and keeps a Buy rating on the shares. The Myonexus alliance augments Sarepta's pipeline with three clinical stage gene therapy programs along with two preclinical efforts, "significantly expanding" its focus and exposure to gene therapy and genetic medicine, Chattopadhyay tells investors in a research note.
PFE Pfizer
$35.86

0.35 (0.99%)

04/16/18
NORL
04/16/18
NO CHANGE
NORL
Outperform
Pfizer appears to be BioLife Solutions customer, says Northland
Northland analyst Suraj Kalia believes Pfizer (PFE) has never publicly announced itself as a customer of BioLife Solutions (BLFS), but a link to a presentation apparently made at the AAPS conference seems to highlight Pfizer' use of BioLife's CryoStor cryopreservation medium in its CAR-T program. Kalie noted this is the first time he has learned of Pfizer being a customer and of the use of BioLife's CryoStor being used in allogeneic CAR-T applications, both of which he finds interesting. Kalia has an Outperform rating on BioLife.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.
SLDB Solid Biosciences
$21.71

-0.79 (-3.51%)

05/10/18
LEER
05/10/18
NO CHANGE
Target $28
LEER
Outperform
Solid Biosciences price target raised to $28 from $14 at Leerink
Leerink analyst Joseph Schwartz raised his price target on Solid Biosciences to $28 from $14 after he updated his model to reflect Q1 results and increased his probability of success estimate for SGT-001 to 30% from 20%. His probability of success estimate for SB-001 is unchanged at 20%, he noted. Schwartz keeps an Outperform rating on Solid Biosciences shares.
03/15/18
03/15/18
NO CHANGE

Sarepta lead solidified with Solid clinical hold, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says Sarepta Therapeutics' (SRPT) lead in developing a gene therapy for Duchenne muscular dystrophy is potentially solidified after Solid Biosciences' (SLDB) Phase 1/2 clinical program was placed on clinical hold. Based on the differences between Sarepta's and Solid's vectors and the evolving safety profiles of the two competing approaches, the analyst would be a buyer of Sarepta's stock "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He keeps a Buy rating on Sarepta shares with a $92 price target.
04/02/18
LEER
04/02/18
NO CHANGE
Target $14
LEER
Outperform
Solid Biosciences price target lowered to $14 from $36 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Solid Biosciences to $14 from $36 saying that while it was able to withstand several initial concerns that were addressed when the company was going public - including preclinical safety, a board member resignation, manufacturing issues -, Solid Biosciences' recent clinical hold announcement was "the straw that broke the camel's back" resulting in a massive selloff. The analyst reiterates an Outperform rating on the shares.
03/15/18
LEER
03/15/18
NO CHANGE
LEER
Outperform
Solid Biosciences selloff on clinical hold news may be premature, says Leerink
Leerink analyst Joseph Schwartz says Solid Biosciences' disclosure of a clinical hold on Phase 1/2 IGNITE DMD trial comes as a surprise. However, the analyst believes it is too early to throw in the towel on SGT-001. In fact, a "knee-jerk reaction" may present an attractive buying opportunity for investors due to small sample size, a lack of other noteworthy adverse effects, and patients positive recovery since the incident. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

FPAY

FlexShopper

$1.16

-0.69 (-37.30%)

20:42
09/25/18
09/25
20:42
09/25/18
20:42
Syndicate
FlexShopper 10M unit Secondary priced at $1.00 »

acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

IGC

IGC, Inc

$2.32

-0.22 (-8.66%)

20:40
09/25/18
09/25
20:40
09/25/18
20:40
Hot Stocks
IGC to enter Hemp/CBD-infused energy drink space »

India Globalization…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$57.10

-0.33 (-0.57%)

20:32
09/25/18
09/25
20:32
09/25/18
20:32
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta Air Lines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

SPY

SPDR S&P 500 ETF Trust

$290.73

-0.36 (-0.12%)

, SPX

S&P 500

$0.00

(0.00%)

20:32
09/25/18
09/25
20:32
09/25/18
20:32
Periodicals
Trump considering keeping Deputy AG Rosenstein, WSJ says »

Donald Trump has…

SPY

SPDR S&P 500 ETF Trust

$290.73

-0.36 (-0.12%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCE

Arco Platform

$0.00

(0.00%)

20:31
09/25/18
09/25
20:31
09/25/18
20:31
Syndicate
Arco Platform 11.111M share IPO priced at $17.50 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

KMX

CarMax

$75.87

-0.01 (-0.01%)

20:25
09/25/18
09/25
20:25
09/25/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

AINC

Ashford

$75.95

-11.75 (-13.40%)

20:23
09/25/18
09/25
20:23
09/25/18
20:23
Syndicate
Ashford 270K share Secondary priced at $74.50 »

UBS, RBC Capital and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 26

    Sep

ANAB

AnaptysBio

$94.68

-7.25 (-7.11%)

20:21
09/25/18
09/25
20:21
09/25/18
20:21
Syndicate
AnaptysBio 2.2M share Secondary priced at $94.46 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SF

Stifel Financial

$53.96

-0.08 (-0.15%)

20:01
09/25/18
09/25
20:01
09/25/18
20:01
Hot Stocks
Stifel Financial and Everbright Sun Hung Kai establish strategic partnership »

Stifel Financial and Hong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

I

Intelsat

$27.08

4.365 (19.22%)

19:59
09/25/18
09/25
19:59
09/25/18
19:59
Hot Stocks
Intelsat and Azercosmos announce successful satellite launch »

Intelsat S.A. and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.88

0.66 (2.18%)

19:49
09/25/18
09/25
19:49
09/25/18
19:49
Hot Stocks
Breaking Hot Stocks news story on Skyline »

Centerbridge Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

KBH

KB Home

$25.29

-0.24 (-0.94%)

, AIR

AAR Corp.

$46.03

1.04 (2.31%)

19:28
09/25/18
09/25
19:28
09/25/18
19:28
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: KB…

KBH

KB Home

$25.29

-0.24 (-0.94%)

AIR

AAR Corp.

$46.03

1.04 (2.31%)

VSTM

Verastem

$7.15

-1.74 (-19.57%)

CGIX

Cancer Genetics

$1.22

-0.01 (-0.81%)

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

NLSN

Nielsen

$27.21

0.055 (0.20%)

CYH

Community Health

$3.41

-0.08 (-2.29%)

AUPH

Aurinia Pharmaceuticals

$5.89

0.02 (0.34%)

GOOS

Canada Goose

$58.00

-0.04 (-0.07%)

ABBV

AbbVie

$93.78

0.34 (0.36%)

NKE

Nike

$84.79

0.52 (0.62%)

CTAS

Cintas

$212.99

1.81 (0.86%)

LULU

Lululemon

$158.42

1.04 (0.66%)

CONE

CyrusOne

$64.65

-0.6 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

  • 05

    Oct

  • 26

    Sep

CBS

CBS

$56.54

-0.07 (-0.12%)

19:19
09/25/18
09/25
19:19
09/25/18
19:19
Hot Stocks
CBS names Richard Parsons interim chairman »

Richard Parsons has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ZUMZ

Zumiez

$27.00

-0.55 (-2.00%)

19:09
09/25/18
09/25
19:09
09/25/18
19:09
Initiation
Zumiez initiated  »

Zumiez initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$97.54

0.26 (0.27%)

, TJX

TJX

$110.33

0.605 (0.55%)

19:03
09/25/18
09/25
19:03
09/25/18
19:03
Initiation
Ross Stores, TJX initiated  »

Ross Stores initiated…

ROST

Ross Stores

$97.54

0.26 (0.27%)

TJX

TJX

$110.33

0.605 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MNOV

MediciNova

$11.68

-0.17 (-1.43%)

19:01
09/25/18
09/25
19:01
09/25/18
19:01
Hot Stocks
MediciNova announces 'positive' FDA feedback on Phase 3 plan for MN-166 »

MediciNova announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$140.00

-0.56 (-0.40%)

18:58
09/25/18
09/25
18:58
09/25/18
18:58
Initiation
PVH Corp. initiated  »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

GOOS

Canada Goose

$58.00

-0.04 (-0.07%)

18:50
09/25/18
09/25
18:50
09/25/18
18:50
Initiation
Canada Goose initiated  »

Canada Goose initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.91

-0.55 (-0.68%)

18:47
09/25/18
09/25
18:47
09/25/18
18:47
Periodicals
Philip Morris hits streets to sell older smokers on new devices, Bloomberg says »

Philip Morris is moving a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

URBN

Urban Outfitters

$40.06

-0.32 (-0.79%)

18:45
09/25/18
09/25
18:45
09/25/18
18:45
Initiation
Urban Outfitters initiated at DA Davidson »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

SVMK

SurveyMonkey

$0.00

(0.00%)

18:35
09/25/18
09/25
18:35
09/25/18
18:35
Syndicate
SurveyMonkey 15M share IPO priced at $12.00 »

The shares are expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LULU

Lululemon

$158.42

1.04 (0.66%)

18:34
09/25/18
09/25
18:34
09/25/18
18:34
Initiation
Lululemon initiated at DA Davidson »

Lululemon initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROL

Rollins

$62.46

0.74 (1.20%)

, ANDV

Andeavor

$157.60

-1.41 (-0.89%)

18:30
09/25/18
09/25
18:30
09/25/18
18:30
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

ROL

Rollins

$62.46

0.74 (1.20%)

ANDV

Andeavor

$157.60

-1.41 (-0.89%)

INGN

Inogen

$258.49

5.5 (2.17%)

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

MPC

Marathon Petroleum

$85.04

-0.78 (-0.91%)

GTX

Garrett Motion

$0.00

(0.00%)

ACET

Aceto

$2.83

-0.09 (-3.08%)

HON

Honeywell

$165.59

0.12 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 09

    Oct

  • 19

    Oct

  • 27

    Nov

TJX

TJX

$110.33

0.605 (0.55%)

18:27
09/25/18
09/25
18:27
09/25/18
18:27
Initiation
TJX initiated at DA Davidson »

TJX initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYH

Community Health

$3.41

-0.08 (-2.29%)

18:25
09/25/18
09/25
18:25
09/25/18
18:25
Hot Stocks
Breaking Hot Stocks news story on Community Health »

Community Health up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.